SEC Comment Letter 0000000000-24-014152 to Nok Therapeutics, Inc. (CIK 0002038166)
Nok Therapeutics, Inc. (CIK 0002038166)
Date: Dec. 20, 2024 · CIK: 0002038166 · Accession: 0000000000-24-014152
AI Filing Summary & Sentiment
File numbers found in text: 024-12511
Letter
December 20, 2024 Robert Lewis President, Chief Executive Officer and Director NӦK Therapeutics, Inc. 1452 N. US HWY 1, Suite 123 Ormond Beach, FL 32174 Re:NӦK Therapeutics, Inc. Amendment No. 5 to the Offering Statement on Form 1-A Filed December 17, 2024 File No. 024-12511 Dear Robert Lewis: We have reviewed your amended offering statement and have the following comment. Please respond to this letter by amending your offering statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your offering statement and the information you provide in response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our December 13, 2024 letter. Amendment No. 5 to Offering Statement on Form 1-A Use of Proceeds, page 18 1.We re-issue prior comment number 2. Because the unsecured notes to be repaid with the proceeds of this offering were issued within the past year, please describe how the proceeds from the unsecured notes were used by the company. Refer to Instruction 6 to Item 6 of Form 1-A. Please contact Vanessa Robertson at 202-551-3649 or Lynn Dicker at 202-551-3616 if you have questions regarding comments on the financial statements and related matters. Please contact Chris Edwards at 202-551-6761 or Alan Campbell at 202-551-4224 with any other questions.
December 20, 2024 Page 2 Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jim Byrd
Show Raw Text
December 20, 2024
Robert Lewis
President, Chief Executive Officer and Director
NӦK Therapeutics, Inc.
1452 N. US HWY 1, Suite 123
Ormond Beach, FL 32174
Re:NӦK Therapeutics, Inc.
Amendment No. 5 to the Offering Statement on Form 1-A
Filed December 17, 2024
File No. 024-12511
Dear Robert Lewis:
We have reviewed your amended offering statement and have the following comment.
Please respond to this letter by amending your offering statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your offering statement and the information you
provide in response to this letter, we may have additional comments. Unless we note
otherwise, any references to prior comments are to comments in our December 13, 2024
letter.
Amendment No. 5 to Offering Statement on Form 1-A
Use of Proceeds, page 18
1.We re-issue prior comment number 2. Because the unsecured notes to be repaid with
the proceeds of this offering were issued within the past year, please describe how the
proceeds from the unsecured notes were used by the company. Refer to Instruction 6
to Item 6 of Form 1-A.
Please contact Vanessa Robertson at 202-551-3649 or Lynn Dicker at 202-551-3616
if you have questions regarding comments on the financial statements and related
matters. Please contact Chris Edwards at 202-551-6761 or Alan Campbell at 202-551-4224
with any other questions.
December 20, 2024
Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jim Byrd